Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
Hematological Oncology · 2025
DOI: 10.1002/hon.70025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Hazim S Ababneh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (18F‐FDG PET/CT) parameters have shown a significant prognostic role in relapsed/refractory large B‐cell lymphoma (LBCL) patients undergoing CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy. While a substantial body of evidence exists on the prognostic value of PET/CT parameters in peri‐CAR T setting, data available on the prognostic value of PET/CT parameters following CAR T‐cell therapy failure is lacking. Therefore, we sought to analyze the PET/CT scans of LBCL patients who experienced post‐CAR T relapsed/progressive disease and subsequently received salvage therapies. Thirty‐three LBCL patients who had PET‐CT scans done demonstrating post‐CAR T failure and then received salvage therapies [as a first salvage modality: RT alone, nine patients; combined modality therapy (CMT), seven patients; systemic therapy (ST) alone, 17 patients] were analyzed. The median follow‐up after CAR T‐cell infusion was 11.7 months [interquartile range (IQR): 5.1–24.4 months], and the median follow‐up after post‐CAR T salvage therapy was 7.3 months (IQR: 2.7–19.1 months). The median timeframe for the PET scan showing post‐CAR T failure was 2.4 months (IQR: 0.96–5.0 months). On univariable analysis from salvage therapy start date, high metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were associated with inferior overall survival (OS) (Hazard ratio –HR = 8.4, p < 0.0001; HR = 3.2, p = 0.01, respectively). High MTV was associated with a non‐significant trend of inferior progression‐free survival (PFS) (HR = 3.5, p = 0.09). High maximum standardized uptake value (SUVmax) was not associated with inferior OS or inferior PFS. On multivariable analysis from salvage therapy start date, high MTV (HR = 4.6, 95% CI: 1.5–14.3, p = 0.009) was identified to be an independent prognostic factor for inferior OS. High International Prognostic Index (IPI) (≥ 3) at the time of salvage therapy (HR = 2.5, 95% CI: 1.1–5.6, p = 0.02) was significantly associated with inferior PFS. Our study shows that semiquantitative PET/CT metrics, especially MTV, are significant prognostic indicators of overall survival in this highly refractory population after CAR T‐cell therapy failure, potentially refining prognostic and treatment approaches beyond conventional parameters like IPI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Hazim S Ababneh
Zitieren
APA
Ababneh, H. S., Frigault, M. J., Ng, A. K., & Patel, C. G. (2025). Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70025
Vancouver
Ababneh HS, Frigault MJ, Ng AK, Patel CG. Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70025
BibTeX
@article{Ababneh2025,
author = {Ababneh, Hazim S and Frigault, Matthew J and Ng, Andrea K and Patel, Chirayu G},
title = {Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70025}
}
EUVIMED